Journal of Liver Cancer最新文献_第8页

Ras Mitogen-activated Protein Kinase Signaling and Kinase Suppressor of Ras as Therapeutic Targets for Hepatocellular Carcinoma. Ras丝裂原激活的蛋白激酶信号和Ras激酶抑制因子作为肝细胞癌的治疗靶点。

Journal of Liver Cancer Pub Date : 2021-03-01 DOI: 10.17998/jlc.21.1.1

Hyuk Moon, Simon Weonsang Ro

引用次数: 3

Hepatocellular Carcinoma Arising from Hepatocellular Adenoma in an Elderly Male Patient. 老年男性肝细胞腺瘤并发肝细胞癌1例。

Journal of Liver Cancer Pub Date : 2021-03-01 DOI: 10.17998/jlc.21.1.87

Manuel Lim, Jong Man Kim, Ji Eun Kwon, Eun Sung Jeong, Jaehun Yang, Okjoo Lee, Kyeong Deok Kim, Sang Jin Kim, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh

引用次数: 0

A Case of Metastatic Melanoma in the Liver Mimicking Hepatocellular Carcinoma. 模拟肝细胞癌的肝脏转移性黑色素瘤1例。

Journal of Liver Cancer Pub Date : 2021-03-01 DOI: 10.17998/jlc.21.1.92

Jae-Kyoung So, Ji-Yun Hong, Min-Woo Chung, Sung-Bum Cho

引用次数: 0

External Beam Radiotherapy for Hepatocellular Carcinoma: a Review of the Current Guidelines in the East and the West. 外束放疗治疗肝细胞癌:东西方现行指南综述。

Journal of Liver Cancer Pub Date : 2021-03-01 DOI: 10.17998/jlc.21.1.25

Sang Min Yoon

引用次数: 4

Update on Pathologic and Radiologic Diagnosis of Combined Hepatocellular-Cholangiocarcinoma. 肝细胞-胆管合并癌的病理及影像学诊断进展。

Journal of Liver Cancer Pub Date : 2021-03-01 DOI: 10.17998/jlc.21.1.12

Hyungjin Rhee, Jae Hyon Park, Young Nyun Park

{"title":"Update on Pathologic and Radiologic Diagnosis of Combined Hepatocellular-Cholangiocarcinoma.","authors":"Hyungjin Rhee, Jae Hyon Park, Young Nyun Park","doi":"10.17998/jlc.21.1.12","DOIUrl":"https://doi.org/10.17998/jlc.21.1.12","url":null,"abstract":"Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a malignant primary liver carcinoma characterized by the unequivocal presence of both hepatocytic and cholangiocytic differentiation within the same tumor. Recent research has highlighted that cHCC-CCAs are more heterogeneous than previously expected. In the updated consensus terminology and WHO 2019 classification, \"classical type\" and \"subtypes with stem-cell features\" of the WHO 2010 classification are no longer recommended. Instead, it is recommended that the presence and percentages of various histopathologic components and stem-cell features be mentioned in the pathologic report. The new terminology and classification enable the exchange of clearer and more objective information about cHCC-CCAs, facilitating multi-center and multi-national research. However, there are limitations to the diagnosis of cHCC-CCA by imaging and biopsy. cHCC-CCAs showing typical imaging findings of HCC could be misdiagnosed as HCC and subjected to inappropriate treatment, if other clinical findings are not sufficiently considered. cHCC-CCAs showing at least one of the CCA-like imaging features or unusual clinical features should be subjected to biopsy. There may be a sampling error for the biopsy diagnosis of cHCC-CCA. An optimized diagnostic algorithm integrating clinical, radiological, and histopathologic information of biopsy is required to resolve these diagnostic pitfalls.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"21 1","pages":"12-24"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2d/f9/jlc-21-1-12.PMC10035725.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10113921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry. 韩国的肝细胞癌：2015 年韩国全国癌症登记分析。

Journal of Liver Cancer Pub Date : 2021-03-01 Epub Date: 2021-03-31 DOI: 10.17998/jlc.21.1.58

Jun Sik Yoon, Han Ah Lee, Hwi Young Kim, Dong Hyun Sinn, Dong Ho Lee, Suk Kyun Hong, Ju-Yeon Cho, Jonggi Choi, Young Chang, Hyun-Joo Kong, Eunyang Kim, Young-Joo Won, Jeong-Hoon Lee

{"title":"Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry.","authors":"Jun Sik Yoon, Han Ah Lee, Hwi Young Kim, Dong Hyun Sinn, Dong Ho Lee, Suk Kyun Hong, Ju-Yeon Cho, Jonggi Choi, Young Chang, Hyun-Joo Kong, Eunyang Kim, Young-Joo Won, Jeong-Hoon Lee","doi":"10.17998/jlc.21.1.58","DOIUrl":"10.17998/jlc.21.1.58","url":null,"abstract":"Background/aims: Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer-related death in Korea. This study evaluated the characteristics of Korean patients newly diagnosed with HCC in 2015.Methods: Data from the Korean Primary Liver Cancer Registry (KPLCR), a representative sample of patients newly diagnosed with HCC in Korea, were analyzed. A total of 1,558 patients with HCC registered in the KPLCR in 2015 were investigated.Results: The median age was 61.0 years (interquartile range, 54.0-70.0 years), and men accounted for 79.7% of the subjects. Hepatitis B virus infection was the most common underlying liver disease (58.1%). According to the Barcelona Clinic Liver Cancer (BCLC) staging system, stage 0, A, B, C, and D HCCs accounted for 14.2%, 31.5%, 7.6%, 39.0%, and 7.8% of patients, respectively. Transarterial therapy (32.1%) was the most commonly performed initial treatment, followed by surgical resection (23.2%), best supportive care (20.2%), and local ablation therapy (10.7%). Overall, 34.5% of patients were treated in accordance with the BCLC guidelines: 59.2% in stage 0/A, 48.4% in stage B, 18.1% in stage C, and 71.6% in stage D. The 1-, 3-, and 5-year OS rates were 67.1%, 50.9%, and 27.0%, respectively.Conclusions: In 2015, approximately 45% of Korean HCC cases were diagnosed at a very early or early stage, and 35% of patients underwent potentially curative initial treatment. BCLC guidance was followed in 34.5% of patients; in patients with stage B or C disease, there was relatively low adherence.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"21 1","pages":"58-68"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/26/jlc-21-1-58.PMC10035724.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10109658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Huge Hepatic Angiomyolipoma Mimicking Low Grade Hepatocellular Carcinoma. 类似低级别肝癌的巨大肝血管平滑肌脂肪瘤。

Journal of Liver Cancer Pub Date : 2021-03-01 DOI: 10.17998/jlc.21.1.76

Hyeo Seong Hwang, Dae Hoon Han

引用次数: 0

Advanced Stage Hepatocellular Carcinoma Successfully Treated with Liver-directed Concurrent Chemoradiotherapy and Sequential Transarterial Radio-embolization. 肝定向同步放化疗和序贯经动脉放射栓塞成功治疗晚期肝细胞癌。

Journal of Liver Cancer Pub Date : 2021-03-01 DOI: 10.17998/jlc.21.1.97

Minho Noh, Beom Kyung Kim, Seung Up Kim

引用次数: 0

Incidence and Clinical Features of Hepatitis C Virus-associated Hepatocellular Carcinoma Patients without Liver Cirrhosis in Hepatitis B Virus-endemic Area. 乙型肝炎病毒流行区无肝硬化丙型肝炎病毒相关肝细胞癌的发病率及临床特点

Journal of Liver Cancer Pub Date : 2021-03-01 DOI: 10.17998/jlc.21.1.34

Jongbeom Shin, Jung Hwan Yu, Young-Joo Jin, Jin-Woo Lee

{"title":"Incidence and Clinical Features of Hepatitis C Virus-associated Hepatocellular Carcinoma Patients without Liver Cirrhosis in Hepatitis B Virus-endemic Area.","authors":"Jongbeom Shin, Jung Hwan Yu, Young-Joo Jin, Jin-Woo Lee","doi":"10.17998/jlc.21.1.34","DOIUrl":"https://doi.org/10.17998/jlc.21.1.34","url":null,"abstract":"Background/objective: Hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC) is rarely observed in patients without liver cirrhosis (LC). We evaluated the incidence and clinical feature of HCV-associated HCC patients with or without LC.Methods: The medical records of 1,516 patients diagnosed as having primary HCC at our hospital between January 2005 and December 2017 were retrospectively reviewed. Of these, 154 (10.2%) HCV-associated HCC patients were analyzed. LC was diagnosed histologically or clinically.Results: Seventeen (11.0%) of the 154 patients had non-cirrhotic HCC, and all were of Child-Turcotte-Pugh (CTP) class A, Among the 17 patients, 88.2% were male, all had nodular type HCC, and only 2 (11.8%) were under HCC surveillance. Median overall survival (OS) of HCV-associated HCC patients with and without LC was 15 months and 37 months, respectively. Cumulative OS rates were not different between non-cirrhotic patients and cirrhotic patients with CTP class A (P=0.229). Cumulative OS rates were significantly higher in non-cirrhotic patients than in cirrhotic patients of CTP class B (P<0.001) or C (P<0.001). Multivariate analyses showed serum AST (hazard ratio [HR] 1.01, P=0.003) and AFP levels (HR 1.01, P=0.016), antiviral therapy (HR 0.25, P=0.022), and LC of CTP class B (HR, 5.24, P=0.006) or C (HR 21.79, P<0.001) were significantly associated with prognosis in HCV-associated HCC patients.Conclusions: HCC in a non-cirrhotic liver was found in 11% of HCV-associated HCC patients. OSs of HCV-associated HCC patients were better in those of CTP A, regardless of LC than in those with LC of CTP class B or C.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"21 1","pages":"34-44"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8e/0a/jlc-21-1-34.PMC10035726.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9736411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ruptured Massive Hepatocellular Carcinoma Cured by Transarterial Chemoembolization. 经动脉化疗栓塞治疗破裂的大块肝癌。

Journal of Liver Cancer Pub Date : 2020-09-01 DOI: 10.17998/jlc.20.2.154

Ji Eun Lee, Joong-Won Park, In Joon Lee, Bo Hyun Kim, Seoung Hoon Kim, Hyun Beom Kim

引用次数: 0